Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals' stock has been impacted by strong revenue forecasts and growth, the acquisition of Mersana, a licensing agreement with Ipsen, analyst ratings, insider trading, institutional investor activity, Q3 2024 financial results, and stock price fluctuation. The company announced preliminary 2025 net product revenue of $155.4 million for OJEMDA, representing a 172% year-over-year growth. Day One and Ipsen entered an exclusive licensing agreement to commercialize tovorafenib outside the U.S., which included an upfront payment of approximately $111 million in cash and equity investment. Multiple analysts have issued "Buy" or "Overweight" ratings with price targets ranging from $16.00 to $27.00 in late 2025. Over the past six months, company insiders have made sales of DAWN stock. There has been significant institutional investor activity. The company reported strong Q3 2024 results with OJEMDA net product revenue of $20.1 million, a 145% increase over Q2 2024, and total prescriptions growing by 159%.

For Day One Biopharmaceuticals' products, specifically OJEMDA, some demand seasonality has been observed. The company noted some seasonality in January for OJEMDA prescriptions, followed by a rebound in April, which was one of the strongest months for new patient starts since launch. Despite this, the company has consistently seen quarterly growth since launch, reinforcing OJEMDA's position as a foundational revenue driver.

Day One Biopharmaceuticals, Inc. (DAWN) is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for patients with genetically defined cancers. The company operates in the Biotechnology: Pharmaceutical Preparations industry, addressing unmet needs in pediatric cancer, particularly pediatric low-grade glioma (pLGG), and extending its expertise to adult oncology. Its major products include OJEMDA (tovorafenib), DAY301, VRK1 Inhibitor, and Emi-Le.

Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, California, United States. While its primary focus for commercialization has been the U.S. market, the company plans to expand OJEMDA commercially beyond the U.S. through global partnerships.

Day One Biopharmaceuticals has generally maintained a positive brand reputation over the past year, largely driven by the strong performance and demand for its lead product, OJEMDA. OJEMDA has shown robust demand and increasing market penetration, with significant year-over-year and quarter-over-quarter revenue growth. Wall Street analysts have largely been bullish on DAWN stock, with a consensus rating of "Moderate Buy" and optimistic price targets. The strategic acquisition of Mersana and the introduction of new pipeline programs enhance the company's development potential. The company reported a solid financial position with approximately $441 million in cash and investments as of year-end 2025. However, the company disclosed that most of its business came from three customers, with one representing over 66% of sales, indicating an "extreme concentration risk." The announcement of the retirement of a co-founder and Head of Research and Development at the end of 2024 was noted as surprising and could potentially lead to some instability.

Day One Biopharmaceuticals, Inc. has a mixed ownership structure. Approximately 60.59% of the company's stock is owned by institutional investors, 1.65% by insiders, and 37.77% by public companies and individual investors. Major institutional owners include Fmr Llc, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, Vanguard Group Inc, Deerfield Management Company, L.p. (series C), Franklin Resources Inc, Rubric Capital Management LP, State Street Corp and Vestal Point Capital, LP. Peter Kolchinsky is noted as owning the most shares among individual investors.